13FPulse
中
GL

GLUE MONTE ROSA THERAPEUTICS INC

2026Q2 · CUSIP 61225M102 · Sector: Healthcare & Biotech

Cooling

Net holder growth weakened from last quarter

Funds that own it
189
Institutions that reported holding it to the SEC
Net decrease in holders
1
Last quarter 190 → now 189
How unusual is that
Below average
Stronger than only 32% of US stocks
What the filings say, in one paragraph

189 funds held GLUE at the end of 2026Q2, down 1 from the quarter before. Buying has come off its highs, but funds are not exiting. On the business itself, revenue over the last 12 months was $29M(YoY -83.9%), return on equity is -33.1%. GLUE has had 3 buying rushes in its history, and the price moved -38.8% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector.

How many funds owned it, quarter by quarter

Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.

2021Q3: holders=56 2021Q4: holders=53 2022Q1: holders=53 2022Q2: holders=57 2022Q3: holders=70 2022Q4: holders=67 2023Q1: holders=68 2023Q2: holders=67 2023Q3: holders=71 2023Q4: holders=71 2024Q1: holders=68 2024Q2: holders=75 2024Q3: holders=82 2024Q4: holders=104 2025Q1: holders=104 2025Q2: holders=115 2025Q3: holders=128 2025Q4: holders=161 2026Q1: holders=190 2026Q2: holders=189 -33 -16.5 +0 +16.5 +33 47124200 21Q322Q122Q323Q123Q324Q124Q325Q125Q326Q126Q2 Net change in holders (bars) Total funds holding (line)

What happened after each past buying rush 3 times in its history

Quarter of the rush How unusual then Price, next 3 months Price, next 6 months
2026Q1 Top 20% — —
2025Q4 Top 20% -2.7% —
2022Q3 Top 20% -25.5% -38.8%

These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.

Show all the numbers (large funds, value held, options…) ▾
Of them, large funds
98
Change in large funds
-1
Total value they hold
$2.2B
Funds buying for the first time
28
Funds that sold out entirely
29
Price change that quarter
-20.5%
Funds holding puts (bearish)
2
Funds holding calls (bullish)
6

These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.

8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.

Fundamentals

PE (TTM)
—
EPS (TTM)
$-1.76
EPS YoY
-540.0%
Revenue (TTM)
$0.0B
Revenue YoY
-83.9%
Net margin
—
ROE
-33.1%
Debt ratio
29.5%
FCF (TTM)
-$32M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS
2021-09-30: EPS -0.43 2021-12-31: EPS -6.08 2022-03-31: EPS 0.51 2022-06-30: EPS -0.57 2022-09-30: EPS -0.58 2022-12-31: EPS -1.66 2023-03-31: EPS -0.65 2023-06-30: EPS -0.71 2023-09-30: EPS -0.70 2023-12-31: EPS -0.57 2024-03-31: EPS -0.53 2024-06-30: EPS -0.43 2024-09-30: EPS -0.29 2024-12-31: EPS 0.27 2025-03-31: EPS 0.57 2025-06-30: EPS -0.15 2025-09-30: EPS -0.33 2025-12-31: EPS -0.55 2026-03-31: EPS -0.45 2026-06-30: EPS -0.43 0M 42M 85M $M -6.69 -3.03 0.63 20212022202320242025202606/26 Revenue EPS

Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time
10 26 42 20252026

P/E = close around day 47 after quarter-end ÷ TTM EPS then; this is a consistent valuation date, not the company’s actual filing date; loss quarters hidden

Quarterly free cash flow
-47M41M129M 2020202120222023202420252026
Latest quarter $-39M (2026-03-31)

FCF = operating cash flow − capex, computed from SEC XBRL; banks/insurers have no standard cash-flow structure and are hidden

As of 2026-06-30 · SEC filings (XBRL)

Email me the next update

2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.